Insomnia in Patients with Psychiatric Disorders: Causes, Consequences, Best Practices, and Emerging Treatments

Insomnia in Patients with Psychiatric Disorders: Causes, Consequences, Best Practices, and Emerging Treatments

On-Demand Webcast
FACULTY

Karl Doghramji, MD
Professor of Psychiatry and Director, Sleep Disorders Center
Thomas Jefferson University of Sidney Kimmel Medical College
Philadelphia, Pennsylvania

Craig Chepke, MD, FAPA
Adjunct Assistant Professor of Psychiatry, Medical Director
Excel Psychiatric Associates, PA
University of North Carolina School of Medicine
Huntersville, North Carolina

For full faculty bios, please call 609-371-1137.

TO DOWNLOAD SLIDES CLICK HERE.

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

 

INTENDED LEARNERS

This activity is intended for psychiatrists, primary care physicians, psychologists, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Evaluate common root causes and the link between insomnia and psychiatric disorders
  • Review guideline-directed best practices for treatment of primary insomnia
  • Discuss current and emerging agents for the treatment of insomnia, including their pharmacodynamics and safety/efficacy data
ACTIVITY OVERVIEW

To be eligible for documentation of credit, participants must participate in the full activity, and complete the evaluation form. Participants who successfully complete the evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: 10/15/2020
Expiration Date: 10/15/2021
Estimated time to complete: 45 minutes

For questions regarding this educational activity, please call 609-371-1137.

ACCREDITATION INFORMATION

In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

Physicians
NACCME designates this internet live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 0.75 CME credit for activities planned in accordance with the AAPA CME Criteria. This  internet live activity is designated for 0.75 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education internet live activity awards 0.75 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255, for 0.75 contact hours.

CE INFORMATION

Psychologists
As a jointly accredited organization, North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content. Variable credit for partial attendance may not be awarded. Full attendance is required for all CE activities.

Instructional Level: Advanced

Social Workers (ASWB ACE)

NACCME is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NACCME maintains responsibility for this course. Social workers completing this course receive 0.75 Intermediate continuing education credits.

PLANNING COMMITTEE

The planning committee comprises Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN; James Cannon, PhD, MS, PA-C, CAQ-Psy, DFAAPA; Steven R. Chan, MD, MBA; Craig Chepke, MD, FAPA; Karl Doghramji, MD; Rakesh Jain, MD, MPH; Saundra Jain, MA, PSyD, LPC; Catherine Judd, MS, PA-C, CAQPsy, DFAAPA; Edward Kaftarian, MD; Samantha Lau, MSN, FNP-BC, PMHNP-BC; Vladimir Maletic, MD, MS; Ilan Melnick, MD; Andrew Penn, RN, MS, NP, APRN-BC; Charles L. Raison, MD; Douglas L. Noorsdy, MD; William C. Torrey, MD; and Meaghan Benci, Christopher Bowell, Raquel Gaerlan, Samantha Conforti, Greaton Sellers, Mary Johnson, Horacio Rodriguez, Randy Robbin, Michelle Stewart, and Kelly Sweeney.

Independent Clinical Reviewers

The independent clinical reviewers for this activity are:

Douglas L. Noordsy, MD, Clinical Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine; Director of Sports Psychiatry, Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California

William C. Torrey, MD, Professor of Psychiatry; Medical Directory, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire

Nurse Planner

The nurse planner for this activity isAndrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, California; Assistant Clinical Professor, University of California, San Francisco, California

FINANCIAL DISCLOSURE AND CONFLICTS OF INTEREST

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty reported the following:

Dr. Chan: Consultant—Advanced Clinical Scholastic Expeditions; Grant/ Research Support—Davis University of Wisconsin, Madison School of Public Health, University of California; Speakers Bureau—North American Center for Continuing Medical Education, LLC.

Dr. Rakesh Jain: Advisory Board—Alkermes, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva; Advisory Board (spouse)—Otsuka; Consultant—Acadia, Alfasigma USA, Inc., Allergan, Eisai, Evidera, Impel NeuroPharma, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica Pharmaceuticals plc, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva; Consultant (spouse)—Lilly, Otsuka, Pamlab, Sunovion; Grant/Research Support— Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—Alkermes, Allergan, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals; Speakers Bureau (spouse)—Lilly.

Dr. Saundra Jain: Advisory Board—Otsuka; Advisory Board (spouse)—Alkermes, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva; Consultant—Lilly, Otsuka, Pamlab, Sunovion; Consultant (spouse)—Acadia, Alfasigma USA, Inc., Allergan, Eisai, Evidera, Impel NeuroPharma, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica Pharmaceuticals plc, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva; Grant/Research Support (spouse)—Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—Lilly; Speakers Bureau (spouse)—Alkermes, Allergan, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals.

Dr. Kaftarian: Major Stock Shareholder—Owner of Orbit Health Telepsychiatry.

Dr. Melnick: Speaker—Alkermes, Lundbeck, Merck, Neurocrine, Otsuka, Sunovion, Takeda.

Dr. Raison: Consultant—Emory Healthcare, Otsuka Pharmaceuticals, Sage Pharmaceuticals, Usona Institute.

Dr. Carbray, Mr. Dudley, Dr. Harkavy-Friedman, Ms. Judd, Dr. Luo, Ms. Lau, Dr. Noordsy, Mr. Penn, and Dr. Torrey have disclosed no relevant financial relationships with any commercial interests. Ms. Benci, Ms. Gaerlan, Ms. Johnson, Mr. Rodriguez, Mr. Robbin, and Ms. Sweeney have disclosed no relevant financial relationships with any commercial interests. NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations Off-label/unapproved uses of drugs and/or devices will be disclosed prior to the start of each session.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service

Faculty
The faculty has reported the following:

Dr. Chepke: Consultant—Janssen, Neurocrine Biosciences, Otsuka; Grant/Research Support—Acadia, Harmony, Neurocrine Biosciences; Speakers Bureau—Acadia, Allergan, Eisai, Intracellular, Ironshore, Janssen, Jazz, Neurocrine Biosciences, Otsuka, Sunovion, Takeda, Teva.

Dr. Doghramji: Consultant—Eisai, Harmony, Jazz, Merck, Pfizer; Educational/Research Grant—Eisai, Harmony, Inspire, Jazz; Stock—Merck; Stock (Spouse)—Merck.

UNAPPROVED AND INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) of the United States or European Medicines Agency (EMA). Participants are encouraged to consult the EMA-approved or FDA-approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed in this document are the opinions of the presenters and do not necessarily reflect the opinions of Imedex, LLC and/or NACCME, LLC.

HARDWARE/SOFTWARE REQUIREMENTS

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

GRANT SUPPORT

This educational activity is supported by independent educational grants from Eisai.